| Phase 15 trials |
|
Phase 1
|
NCT06736223 |
May → Aug 2025 |
— |
Italfarmaco |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05845567 |
Mar → May 2022 |
— |
Italfarmaco |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05860114 |
Mar → May 2022 |
— |
Italfarmaco |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05492318 |
Mar → May 2022 |
— |
Italfarmaco |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04821063 |
Apr → Jun 2021 |
Duchenne muscular dystrophy, acquired polycythemia vera |
Italfarmaco |
Completed
|
No outcome recorded
|
| Phase 1/25 trials |
|
Phase 1/2
|
NCT01901432 |
Oct 2013 → Jun 2017 |
acquired polycythemia vera |
Italfarmaco |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT01761292 |
Apr 2013 → Dec 2014 |
Duchenne muscular dystrophy |
Italfarmaco |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT00792467 |
Feb 2008 → Jul 2010 |
Hodgkins lymphoma |
Italfarmaco |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT00792740 |
Oct 2007 → Dec 2008 |
Crohn disease |
Italfarmaco |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT00496431 |
May 2007 → Mar 2009 |
Hodgkins lymphoma |
Italfarmaco |
Terminated
|
No outcome recorded
|
| Phase 210 trials |
|
Phase 2
|
NCT06769633 |
Jan 2025 → Dec 2029 expected |
Duchenne muscular dystrophy |
Italfarmaco |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03238235 |
Jan 2018 → Mar 2021 |
Becker muscular dystrophy |
Italfarmaco |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01761968 |
Mar 2013 → Dec 2026 expected |
myeloproliferative neoplasm |
Italfarmaco |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT01261624 |
Oct 2010 → Jun 2012 |
polyarticular juvenile idiopathic arthritis |
Italfarmaco |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT00928707 |
Jun 2009 → Jul 2011 |
acquired polycythemia vera |
Italfarmaco |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00792506 |
Oct 2008 → Jan 2010 |
plasma cell myeloma |
Italfarmaco |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT00792831 |
Feb 2008 → Apr 2009 |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Italfarmaco |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT00606307 |
Dec 2007 → Dec 2008 |
myeloproliferative neoplasm |
Italfarmaco |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00570661 |
Sep 2006 → Aug 2008 |
systemic-onset juvenile idiopathic arthritis |
Italfarmaco |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00442182 |
Sep 2006 → ? |
Schnitzler syndrome, TNF receptor 1-associated periodic fever syndrome |
Radboud University Medical Center |
Unknown
|
No outcome recorded
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT03373968 |
Oct 2017 → Dec 2029 expected |
Duchenne muscular dystrophy |
Italfarmaco |
Recruiting
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT06093672 |
Mar 2024 → Jul 2026 overdue |
acquired polycythemia vera |
Italfarmaco |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05933057 |
Feb 2024 → Feb 2028 expected |
Duchenne muscular dystrophy |
Italfarmaco |
Recruiting
|
No outcome recorded
|
| Phase not applicable1 trial |
| — |
NCT01557452 |
Dec 2011 → Jan 2014 |
juvenile idiopathic arthritis |
Italfarmaco |
Terminated
|
No outcome recorded
|